Pfizer’s transition from pandemic reliance to growth in oncology and rare diseases reflects a strategic pivot, supported by recent acquisitions, despite the challenge of rising debt ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...